A NEW once daily oral treatment
for prostate cancer has been
approved in the European Union.
The approval of androgen
biosynthesis inhibitor Zytiga
(abiraterone acetate) follows an
accelerated review process by the
European Medicines Agency.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Sep 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Sep 11
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.